Sector News

Alexion to create 200 jobs in Dublin expansion

May 12, 2015
Life sciences
Biopharma group Alexion has announced plans for a major expansion of its Irish business.
 
Alexion, which is still building the first page of its planned Dublin base, said it will invest a further € 450 million to extend the facility over the next four years.
 
The expansion will see the US-based specialist in rare and ultra rare diseases construct its first biological manufacturing facility outside the US.
 
The company makes Soliris, one of the world’s most expensive drugs, which is used to treat two rare blood conditions.
 
The drug, which costs in the region of € 430,000 per patient per year, received approval for use in Ireland earlier this year after a protracted negotiation.
 
Alexion expects to create 200 jobs with the investment, nearly doubling the numbers employed in Ireland by the company since its arrival here in 2013.
 
Alexion’s Irish executive VP for global operations Julie O’Neill said the project “further underscores our commitment to Ireland and is enabled by our ability to recruit highly competent and professional personnel”.
 
Tanaiste Joan Burton welcomed the announcement and said the company brought the “miracle of hope to parents of children who have life limiting and life threatening conditions”.
 
Also speaking at the announcement, Minister for Enterprise Richard Bruton characterised Alexion as a “wonderful company” whose founders “have fantastic passion”.
 
By Dominic Coyle
 
Source: Irish Times

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach